Skip to main content

IMS Events Main banner

MRD and Biomarkers

MRD and Biomarkers

Type here to filter the list

(PA-161) Assessing the Clinical Implications and Prognostic Value of Light-chain N-glycosylation in 781 Multiple Myeloma Patients at Diagnosis
(PA-162) Cytokine Dysregulation in Multiple Myeloma: A Comprehensive, Comparative Analysis of Blood and Bone Marrow Profiles
(PA-163) Characteristics of Long-Term Survivors in Multiple Myeloma: Exploring Factors for Cure After Extended Folow-Up
(PA-164) Serum Cholesterol Levels Demonstrate Dynamic Changes Following Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
(PA-165) Testing and Validating a Mass Spectrometry Based Algorithm for Response Assessment in Myeloma
(PA-166) Gene-expression-profiling Plus Integrated Multidisciplinary Approach to Detect New-generation Risk-adapted Prognostic Index in Smoldering Myeloma and Multiple Myeloma (GIMPI): A New Prognostic Score
(PA-167) Measurable Residual Disease (MRD) Dynamics Reveals a Therapeutic Vulnerability State for Early Immunotherapy Interception in Multiple Myeloma (MM)
(PA-168) Advancing Soluble BCMA Quantification in Immunotherapy: Analytical Validation of ELLA versus ELISA for Predicting Toxicity and Response
(PA-169) Mass Spectrometry vs. 10-5 MRD Detection by Next-Generation Flow and Sequencing in Multiple Myeloma: Results from the Cassiopeia Clinical Trial
(PA-170) Whole Genome Sequencing of Cell-free DNA for Assessment of Minimal Residual Disease in High-risk Smoldering Multiple Myeloma
(PA-171) Subclonal and Clonal Progression of Previously Characterized Mutations and Variants of Unknown Significance (VUS) Across a Cohort of Plasma Cell Dyscrasia Patients
(PA-172) The Role of CHIP Mutations in Plasma Cell Dyscrasias: Implications for Clonal Evolution and Risk Stratification
(PA-173) Quantitative CD38 Expression and Clinical Response to Anti-CD38 Therapy in Multiple Myeloma: A Retrospective Cohort Analysis
(PA-174) Patient Perceptions of MRD Negativity as a Treatment Outcome and Regulatory Endpoint in Multiple Myeloma
(PA-175) Comprehensive Characterization and Pharmacological Targeting of Stem‐like Side Population Compartment in Multiple Myeloma
(PA-176) Comparative Evaluation of Advanced Serum-Based Techniques for the Sensitive Detection of Monoclonal Proteins in Multiple Myeloma – A Pilot Study
(PA-177) Circulating Plasma Cells as an Independent Prognostic Marker in Newly Diagnosed Multiple Myeloma: Clinical Correlation and Immunophenotypic Insights
(PA-178) Integrating p53 Protein Expression with Mutation and Copy Number Status Enhances Risk Assessment in Myeloma
(PA-179) Verification and Optimization of VTE Risk Stratification System for Multiple Myeloma in China Based on Review Cohort
(PA-180) Revealing Clonal Evolution and Assessing Immune Reconstitution in Multiple Myeloma Using Next-Generation Sequencing-Based Minimal Residual Disease (NGS-MRD) Analysis
(PA-181) The New IMS / IMWG Consensus Risk Definition Predicts Outcomes with Daratumumab-based Quadruplet Regimens for Multiple Myeloma
(PA-182) Minimal Residual Disease Kinetics in Patients with Multiple Myeloma Receiving First Line Treatment and the Association with their Progression-Free Survival; A Retrospective Study of 323 patients
(PA-183) Bridging the Gap: Conversion of Siemens N-Latex to Binding Site Freelite for Accurate Multiple Myeloma Diagnosis and Risk Stratification
(PA-184) Stem Cell Autograft Minimal Residual Disease Negativity Predicts Improved Outcomes After Autologous Stem Cell Transplant for Multiple Myeloma
(PA-185) Towards the Identification of Novel Circulating Biomarkers Associated with Bone Disease in Multiple Myeloma
(PA-186) Deciphering Genomic Correlates of Differential Treatment Response Kinetics in Multiple Myeloma
(PA-187) Peripheral Blood Clonotypic Mass Spectrometry-based MRD Stratification Identifies Patients at Increased Risk of Progression After Quadruplet Therapy in NDMM
(PA-188) Light Chain Escape in Multiple Myeloma: A Not-so-unusual Phenomenon
(PA-189) Peripheral Residual Disease (PRD) Monitoring by Clonotypic Mass Spectrometry (EASYM) in patients with Newly Diagnosed Multiple Myeloma
(PA-190) 3D Telomere Profiling of MRD in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression
(PA-191) Lymphocyte to Monocyte Ratio at Minimal Residual Disease Assessment Predicted Survival Time Among Myeloma Patients in Complete Response
(PA-192) Refining MRD Surveillance in Multiple Myeloma: Predictive Insights from Ultrasensitive Bone Marrow Analysis
(PA-193) Absolute Lymphocyte Count (ALC) ≥1,000 Is as a Surrogate of Car‑T Cell Expansion and a Readily Available Biomarker to Predict Outcomes in Relapsed/refractory Multiple Myeloma (RRMM)
(PA-194) Detectable Peripheral Blood Measurable Residual Disease (PBMRD) Is Strongly Associated with Early Progression in Newly Diagnosed Multiple Myeloma (NDMM)
(PA-195) Profiling Minimal Residual Disease with Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Patients Receiving BCMA- or GPRC5D-Targeted Agents
(PA-196) Clinical Utility of Quantitative, Mass Spectrometry-based EasyM for MRD Monitoring in Multiple Myeloma: Integration with Established MRD Detection Techniques in a Pan-canadian Real-world Cohort Study
(PA-197) Utilization and Preferences of MRD Testing for Patients with Multiple Myeloma: Insights from a Survey of 251 North American Hematologists And/or Oncologists
(PA-198) Identification of a CAR–Derived Clone by NGS-based MRD After Fully Human BCMA CAR T-Cell Therapy in Multiple Myeloma
(PA-199) Elevated Non-Clonal Bone Marrow Plasma Cell Fraction at Diagnosis Is Associated with Improved Outcomes in Multiple Myeloma
(PA-200) Performance and Additional Benefits of Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight Mass Spectrometry in M-Protein Detection in Plasma Cell Disorders
(PA-201) Delayed and Sustained Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma
(PA-202) Dynamic Changes in Cytogenetic Abnormalities Detected by Serial FISH Predict MRD Status and Outcomes in Multiple Myeloma